400
Participants
Start Date
March 22, 2024
Primary Completion Date
October 22, 2024
Study Completion Date
October 22, 2024
HRV PCV-free
2 doses of HRV PCV-free vaccine are administered orally at Month 0.5 and Month 1.5 (Co-administration Group) and at Day 1 and Month 1 (Staggered Group), according to the immunization schedule for HRV vaccine licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
IPV
3 doses of IPV vaccine are administered intramuscularly at Month 0.5, Month 1.5 and Month 2.5 (Co-administration Group and Staggered Group), according to the recommended schedule for vaccination against poliovirus in China.
GSK Investigational Site, Mianyang
GSK Investigational Site, Yuechi-Guang'an
GSK Investigational Site, Neijiang
GSK Investigational Site, Wenshan
GSK Investigational Site, Wenshan
Lead Sponsor
GlaxoSmithKline
INDUSTRY